63 results
Page 2 of 4
8-K
EX-99.2
eob7b6mfntiygso9 tn
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
95bn049
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
ssimz
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.2
g3bad10s
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.1
uulyum9x
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.2
zjdk93 248saf
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
424B5
49n32pcm3nt
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
jhhf4
19 May 20
Prospectus supplement for primary offering
5:08pm
FWP
i1qnaka nsm72c9nglf
19 May 20
Free writing prospectus
6:06am
FWP
hlm kqigj7d6d
18 May 20
Free writing prospectus
5:02pm
424B5
ouoxob my
18 May 20
Prospectus supplement for primary offering
4:16pm
424B5
9k3iguerqgrvote
18 May 20
Prospectus supplement for primary offering
4:11pm
8-K
EX-10.1
bukd6j5fiajorxn
3 May 19
Gossamer Bio Secures Debt Facility for Up to $150 Million
4:00pm
10-K
j03pdjfbj1zfgbdlkc
22 Mar 19
Annual report
4:45pm
424B4
zzyd4
8 Feb 19
Prospectus supplement with pricing info
4:40pm
FWP
vyl016
30 Jan 19
Free writing prospectus
5:29pm